Ben Biefnes Email

Director, Marketing . Aytu BioScience

Current Roles

Employees:
137
Revenue:
$27.5M
About
Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company's therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients' redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company's strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.
Aytu BioScience Address
373 Inverness Parkway
Centennial, CO
United States

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.